摘要
目的探讨去铁酮单用及合用去铁胺治疗地中海贫血患儿的临床疗效。方法选取我院2017年1月至2017年12月收治的60例地中海贫血患儿,随机分为观察组和对照组各30例。对照组给予去铁酮单药治疗,观察组采用去铁酮联合去铁胺治疗。比较两组患儿的临床治疗效果及不良反应情况。结果治疗后,两组患儿的SF浓度及尿铁排泄情况均较治疗前明显改善,且观察组的SF浓度及尿铁排泄情况均明显优于对照组(P均<0.05)。观察组的临床总有效率为90.00%,明显高于对照组的63.33%(P<0.05)。观察组的不良反应发生率为6.67%,明显低于对照组的30.00%(P<0.05)。结论与单用去铁酮相比,去铁酮联合去铁胺治疗地中海贫血患儿的临床疗效更显著,不良反应少,安全性高,值得临床推广应用。
Objective To explore the clinical curative effect of defriprone alone and combined with deferoxamine in the treatment of children with thalassemia. Methods 60 cases of children with thalassemia admitted to our hospital from January 2017 to December 2017 were selected and randomly divided into observation group and control group, with 30 cases in each group. The control group was only treated with defriprone, while the observation group was treated with defriprone combined with deferoxamine. The clinical treatment effect and adverse reactions were compared between the two groups. Results After treatment, the SF concentration and urine iron excretion of the two groups improved significantly compared with those before treatment, and the SF concentration and urine iron excretion of the observation group were significantly better than those of the control group（all P〈0.05）. The total clinical effective rate of the observation group was 90.00%, significantly higher than 63.33% of the control group（P〈0.05）. The incidence of adverse reactions of the observation group was 6.67%, significantly lower than 30.00% of the control group（all P〈0.05）. Conclusions Compared with the defriprone alone,defriprone combined with deferoxamine in the treatment of children with thalassemia has more significant clinical curative effect, with fewer adverse reactions and high safety, which is worthy of clinical promotion and application.
作者
黄朝晖
曲红
HUANG Zhaohui;QU Hong(The Central Hospital of Panyu District,Guangzhou 511400,China)
出处
《临床医学工程》
2018年第7期933-934,共2页
Clinical Medicine & Engineering
关键词
去铁酮
用去铁胺
地中海贫血
疗效
Defriprone
Deferoxamine
Thalassemia
Curative effect
